Patients' Age Is Important When Setting Priorities

Published Jul 23, 2013
Tromsø, Norway - Several studies on priority setting preferences have shown that people think that differences both in patients’ ageand in remaining lifetime should be taken into account. Researchers from the University of Tromsø in Norway set out to determine what is more important: A patient’s age or their remaining lifetime if left untreated? Survey results from a Norwegian population sample provided strong support for the ‘fair innings’ argument that total lifetime inequalities should be reduced.  Differences in patients’ remaining lifetime without treatment did not matter, implying little support for the ‘end of life’ argument that a short life expectancy makes patients entitled to preferential treatment. When faced with pairwise choices between hypothetical patients, the majority of respondents would prioritise the younger patient even if the older patient had shorter remaining lifetime if left untreated. Professor Jan Abel Olsen, PhD, lead author on the study states, "It is more important to reduce inequalities in people's total lifetime than in their remaining lifetime."  The full study, “Priority Preferences: “End of Life” Does Not Matter, But Total Life Does,” is published inValue in Health.

Value in Health (ISSN 1098-3015) publishes papers, concepts, and ideas that advance the field of pharmacoeconomics and outcomes research as well as policy papers to help health care leaders make evidence-based decisions. The journal is published bi-monthly and has over 8,000 subscribers (clinicians, decision-makers, and researchers worldwide).

International Society for Pharmacoeconomics and Outcomes Research (ISPOR) is a nonprofit, international, educational and scientific organization that strives to increase the efficiency, effectiveness, and fairness of health care resource use to improve health.

For more information: www.ispor.org

Related Stories

Rethinking Medication Adherence: A Stakeholder Blueprint

May 12, 2025

Value in Health, the official journal of ISPOR—The Professional Society for Health Economics and Outcomes Research, announced today the publication of a report from its Medication Adherence and Persistence Special Interest Group that provides valuable insights into the perspectives of key stakeholders on interventions to improve medication adherence. The report, “Stakeholders’ Perspectives on Medication Adherence Enhancing Interventions: An ISPOR Report,” was published in the May 2025 issue of Value in Health.

New Research Reveals Surprising Trends in Women's Health Economics Authorship

May 12, 2025

Value in Health, the official journal of ISPOR announced the publication of new research analyzing women's representation in authorship of papers submitted to and published in Value in Health. The report, “How Well Are Women Represented in Authorship in HEOR? An Analysis of Value in Health: An ISPOR Report,” was published in the May 2025 issue of Value in Health.

Redefining Value in Care for Alzheimer's Disease and Dementia

Apr 8, 2025

Value in Health, the official journal of ISPOR—The Professional Society for Health Economics and Outcomes Research, announced the publication of a special themed section of research papers that provide crucial insights into the complex health economics of Alzheimer's disease and related dementias (ADRD), offering a roadmap for future research and policy as the aging population grows and novel treatments emerge.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×